000282918 001__ 282918
000282918 005__ 20251218103446.0
000282918 0247_ $$2doi$$a10.5281/ZENODO.17753486
000282918 037__ $$aDZNE-2025-01379
000282918 1001_ $$0P:(DE-2719)9001970$$aHampton Leonard$$b0
000282918 245__ $$aDataset: Global Parkinson's Genetics Program Data Release 11, v6
000282918 260__ $$bZenodo$$c2025
000282918 3367_ $$2BibTeX$$aMISC
000282918 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1765985104_5347
000282918 3367_ $$026$$2EndNote$$aChart or Table
000282918 3367_ $$2DataCite$$aDataset
000282918 3367_ $$2ORCID$$aDATA_SET
000282918 3367_ $$2DINI$$aResearchData
000282918 520__ $$aIn December 2025, GP2 announced the 11th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 20,842 additional genotyped participants, 17,153 additional WGS participants, and 4,232 additional clinical exomes. The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 103,786 genotyped participants (46,327 PD cases, 28,857 Controls, and 28,602 ‘Other’ phenotypes). The whole genome sequencing (WGS) data now consists of a total of 38,226 sequenced participants (18,219 PD cases, 9,172 Controls, and 10,835 ‘Other’ phenotypes). The clinical exome data now consists of 14,648 samples with PD. Of the 122,317 unique samples with genetic data (NBA, WGS, or clinical exome), 32,897 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: 'Data (DOI 10.5281/zenodo.17753486, release 11) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org.'
000282918 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000282918 588__ $$aDataset connected to DataCite
000282918 7001_ $$aMike Nalls$$b1
000282918 7001_ $$aDan Vitale$$b2
000282918 7001_ $$aMathew Koretsky$$b3
000282918 7001_ $$aKristin Levine$$b4
000282918 7001_ $$aMary Makarious$$b5
000282918 7001_ $$0P:(DE-2719)9001362$$aFang, Zih-Hua$$b6$$udzne
000282918 7001_ $$aJones, Lietsel$$b7
000282918 7001_ $$aSolle, J.$$b8
000282918 773__ $$a10.5281/ZENODO.17753486
000282918 7870_ $$0DZNE-2024-01334$$aLeonard, Hampton et.al.$$dZenodo, 2023$$iRelatedTo$$r$$tDataset: Global Parkinson's Genetics Program Data Release 5, v1
000282918 909CO $$ooai:pub.dzne.de:282918$$pVDB
000282918 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001362$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000282918 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000282918 9141_ $$y2025
000282918 9201_ $$0I:(DE-2719)1210002$$kAG Heutink$$lGenome Biology of Neurodegenerative Diseases$$x0
000282918 980__ $$adataset
000282918 980__ $$aVDB
000282918 980__ $$aI:(DE-2719)1210002
000282918 980__ $$aUNRESTRICTED